Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation

References

• Tablan OC, Anderson LJ, Besser R, et al. Healthcare Infection Control Practices Advisory Committee, Centers for Disease Control and Prevention. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of the CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep. 2004:53(RR-3):1-36
   Google Scholar
• Fagon JY, Chastre J, Hance AJ, et al. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993;94:281-8
   PubMed Web of Science ®Google Scholar
• Leu HS, Kaiser DL, Mori M, et al. Hospital-acquired pneumonia: attributable mortality and morbidity. Am J Epidemiol 1989;129:1258-67
   PubMed Web of Science ®Google Scholar
• Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165:867-903
   PubMed Web of Science ®Google Scholar
• Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002;122:2115-21
   PubMed Web of Science ®Google Scholar
• American Thoracic Society, Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416
   Google Scholar
• J Rello. Bench-to-bedside review: therapeutic options and issues in the management of ventilator-associated bacterial pneumonia. Crit Care 2005;9:259-65
   PubMed Web of Science ®Google Scholar
• Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 2005;11(Suppl. 4):17-32
   PubMed Web of Science ®Google Scholar
• Van Eldere J. Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections. J Antimicrob Chemother 2003;51:347-52
   PubMed Web of Science ®Google Scholar
• Infectious Diseases Society of America. Bad bugs, no drugs. Policy Report, 2004
   Google Scholar
• Chastre J, Wunderink R, Prokocimer P, et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008;36:1089-96
   PubMed Web of Science ®Google Scholar
• Réa-Neto A, Niederman M, Lobo SM, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008;24:2113-26
   PubMed Web of Science ®Google Scholar
• Merchant S, Gast C, Nathwani D, et al. Hospital Resource Utilization with Doripenem Versus Imipenem in the Treatment of Ventilator-Associated Pneumonia. Clin Ther 2008;30:771-33
   Web of Science ®Google Scholar
• Kelton WD, Sadowski RP, Sadowski DA. Simulation with ARENA, 3rd edn. Boston, MA: McGraw-Hill, 2003
   Google Scholar
• Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 2005;23:323-32
   PubMed Web of Science ®Google Scholar
• AnalySource and National Drug Data File (NDDF) data and copyrighted by First DataBank, Inc. 2007
   Google Scholar
• Dasta JF, McLaughlin TP, Mody S, et al. Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med 2005;33:1266-71
   PubMed Web of Science ®Google Scholar
• Paladino JA, Adelman MH, Schentag JJ, et al. Direct costs in patients hospitalized with community-acquired pneumonia after non-response to outpatient treatment with macrolide antibacterials in the US. Pharmacoeconomics 2007;25:677-83
   PubMed Web of Science ®Google Scholar
• Consumer Price Index reports. Bureau of Labor Statistics. U.S. Department of Labor, 2007
   Google Scholar
• Carmeli Y, Troillet N, Karchmer AW, et al. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999;159:1127-32
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Oxford University Press, 2005
   Google Scholar
• Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999;27:887-92
   PubMed Web of Science ®Google Scholar
• Fagon JY, Chastre J, Hance AJ, et al. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993;94:281-8
   PubMed Web of Science ®Google Scholar
• Kollef MH. Ventilator-associated pneumonia. A multivariate analysis. JAMA 1993;270:1965-70
   Google Scholar
• Ost DE, Hall CS, Joseph G, et al. Decision analysis of antibiotic and diagnostic strategies in ventilator-associated pneumonia. Am J Respir Crit Care Med 2003;168:1060-7
   PubMed Web of Science ®Google Scholar
• Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002;122:262-8
   PubMed Web of Science ®Google Scholar
• Alvarez-Lerma F, Alvarez B, Luque P, et al. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study. Crit Care 2006;10:R78
   PubMed Web of Science ®Google Scholar
• Diaz E, Munoz E, Agbaht K, et al. Management of ventilator-associated pneumonia caused by multiresistant bacteria. Curr Opin Crit Care 2007;13:45-50
   PubMed Web of Science ®Google Scholar
• Gastmeier P, Sohr D, Geffers C, et al. Risk factors for death due to nosocomial infection in intensive care unit patients: findings from the Krankenhaus Infektions Surveillance System. Infect Control Hosp Epidemiol 2007;28:466-72
   PubMed Web of Science ®Google Scholar
• Attanasioa E, Russo P, Carunchio G, et al. Cost-effectiveness study of imipenem/cilastatin versus meropenem in intra-abdominal infections. Dig Surg 2000;17:164-72
   PubMed Web of Science ®Google Scholar
• Edwards SJ, Campbell HE, Plumb JM. Cost–utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care. Eur J Health Econ 2006;7:72-8
   PubMedGoogle Scholar
• Iakovlev SV, Beloborodov VB, Sidorenko SV, et al. Multicentre study of comparative efficacy of meropenem and combined regimens for empirical antibacterial therapy of severe nosocomial infections: results of clinical and pharmacoeconomic analysis. Antibiot Khimioter 2006;51:15-27
   PubMedGoogle Scholar
• Barie PS, Rotstein OD, Dellinger EP, et al. The cost-effectiveness of cefepime plus metronidazole versus imipenem/cilastatin in the treatment of complicated intra-abdominal infection. Surg Infect 2004;5:269-80
   PubMedGoogle Scholar
• Morgan CL, Kerr MP. Estimated cost of inpatient admissions and outpatient appointments for a population with epilepsy: a record linkage study. Epilepsy 2004;45:849-54
   Google Scholar
• Jackson BR, Thomas A, Carroll KC, et al. Use of strain typing data to estimate bacterial transmission rates in healthcare settings. Infect Control Hosp Epidemiol 2005;26:638-45
   PubMed Web of Science ®Google Scholar